Organon (OGN) Stock Forecast, Price Target & Predictions
OGN Stock Forecast
Organon stock forecast is as follows: an average price target of $24.00 (represents a 41.84% upside from OGN’s last price of $16.92) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
OGN Price Target
OGN Analyst Ratings
Organon Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 29, 2024 | David Amsellem | Piper Sandler | $24.00 | $18.84 | 27.35% | 41.84% |
Jun 26, 2023 | David Amsellem | Piper Sandler | $34.00 | $20.36 | 66.95% | 100.95% |
Organon Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 1 |
Avg Price Target | - | - | $24.00 |
Last Closing Price | $16.92 | $16.92 | $16.92 |
Upside/Downside | -100.00% | -100.00% | 41.84% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Apr 29, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Mar 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jan 12, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Dec 12, 2023 | Piper Sandler | Overweight | Overweight | Hold |
Nov 09, 2023 | Piper Sandler | Overweight | Overweight | Hold |
Jun 08, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
May 09, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Sep 06, 2022 | Piper Sandler | - | Overweight | Upgrade |
Apr 27, 2022 | Goldman Sachs | - | Buy | Initialise |
Feb 22, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
Organon Financial Forecast
Organon Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $1.60B | $1.52M | $1.61M | $1.54B | $1.49B | $1.54B | $1.58B | $1.57B | $1.60B | $1.60B | $1.59B | $1.51B |
Avg Forecast | $1.58B | $1.57B | $1.61B | $1.60B | $1.59B | $1.56B | $1.61B | $1.57B | $1.55B | $1.57B | $1.57B | $1.54B | $1.49B | $1.51B | $1.53B | $1.52B | $1.57B | $1.58B | $1.52B | $1.57B |
High Forecast | $1.60B | $1.59B | $1.62B | $1.62B | $1.61B | $1.56B | $1.61B | $1.57B | $1.59B | $1.60B | $1.58B | $1.56B | $1.51B | $1.51B | $1.53B | $1.52B | $1.57B | $1.58B | $1.52B | $1.57B |
Low Forecast | $1.57B | $1.55B | $1.59B | $1.59B | $1.58B | $1.56B | $1.61B | $1.56B | $1.52B | $1.56B | $1.55B | $1.53B | $1.48B | $1.51B | $1.53B | $1.52B | $1.57B | $1.58B | $1.52B | $1.57B |
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
Surprise % | - | - | - | - | - | - | - | - | 1.03% | 0.00% | 0.00% | 1.00% | 0.99% | 1.02% | 1.03% | 1.03% | 1.02% | 1.01% | 1.05% | 0.96% |
Organon EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
EBITDA | - | - | - | - | - | - | - | - | $370.00M | $232.00K | $389.00K | $388.00M | $279.00M | $415.00M | $482.00M | $539.00M | $396.00M | $539.00M | $538.00M | $509.00M |
Avg Forecast | $544.49M | $540.07M | $553.02M | $551.27M | $546.99M | $537.44M | $554.05M | $692.28M | $534.05M | $540.97M | $537.88M | $547.26M | $393.78M | $520.33M | $526.71M | $432.62M | $540.61M | $543.51M | $454.95M | $539.18M |
High Forecast | $549.21M | $544.76M | $557.82M | $556.06M | $551.73M | $537.79M | $554.05M | $830.74M | $547.83M | $550.19M | $542.55M | $656.71M | $472.54M | $520.33M | $526.71M | $519.14M | $540.61M | $543.51M | $545.94M | $539.18M |
Low Forecast | $538.57M | $534.20M | $547.01M | $545.28M | $543.48M | $537.09M | $554.05M | $553.83M | $523.71M | $535.48M | $532.03M | $437.81M | $315.03M | $520.33M | $526.71M | $346.09M | $540.61M | $543.51M | $363.96M | $539.18M |
Surprise % | - | - | - | - | - | - | - | - | 0.69% | 0.00% | 0.00% | 0.71% | 0.71% | 0.80% | 0.92% | 1.25% | 0.73% | 0.99% | 1.18% | 0.94% |
Organon Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
Net Income | - | - | - | - | - | - | - | - | $546.00M | $58.00K | $242.00K | $177.00M | $108.00M | $227.00M | $234.00M | $348.00M | $202.00M | $323.00M | $427.00M | $399.00M |
Avg Forecast | $261.49M | $250.23M | $266.90M | $267.55M | $240.46M | $234.67M | $279.39M | $406.95M | $210.66M | $272.81M | $252.66M | $321.70M | $200.87M | $284.83M | $303.30M | $254.31M | $321.42M | $372.32M | $361.09M | $447.37M |
High Forecast | $264.44M | $253.06M | $269.91M | $270.57M | $247.82M | $246.70M | $279.44M | $488.34M | $281.76M | $280.46M | $255.51M | $386.04M | $241.04M | $284.83M | $305.66M | $305.17M | $321.42M | $372.32M | $433.30M | $447.37M |
Low Forecast | $257.79M | $246.69M | $263.13M | $263.77M | $230.65M | $222.65M | $279.33M | $325.56M | $179.06M | $265.16M | $249.08M | $257.36M | $160.70M | $284.83M | $300.94M | $203.45M | $321.42M | $372.32M | $288.87M | $447.37M |
Surprise % | - | - | - | - | - | - | - | - | 2.59% | 0.00% | 0.00% | 0.55% | 0.54% | 0.80% | 0.77% | 1.37% | 0.63% | 0.87% | 1.18% | 0.89% |
Organon SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
SG&A | - | - | - | - | - | - | - | - | $469.00M | $538.00K | $451.00K | $435.00M | $470.00M | $440.00M | $423.00M | $371.00M | $482.00M | $388.00M | $416.00M | $382.00M |
Avg Forecast | $391.10M | $387.92M | $397.22M | $395.97M | $392.89M | $386.03M | $397.97M | $433.85M | $383.60M | $388.57M | $386.35M | $342.96M | $479.30M | $373.75M | $378.33M | $271.12M | $388.31M | $390.39M | $351.79M | $387.28M |
High Forecast | $394.49M | $391.29M | $400.67M | $399.40M | $396.30M | $386.28M | $397.97M | $520.61M | $393.50M | $395.19M | $389.71M | $411.55M | $575.16M | $373.75M | $378.33M | $325.34M | $388.31M | $390.39M | $422.14M | $387.28M |
Low Forecast | $386.84M | $383.71M | $392.91M | $391.66M | $390.37M | $385.78M | $397.97M | $347.08M | $376.17M | $384.62M | $382.15M | $274.37M | $383.44M | $373.75M | $378.33M | $216.89M | $388.31M | $390.39M | $281.43M | $387.28M |
Surprise % | - | - | - | - | - | - | - | - | 1.22% | 0.00% | 0.00% | 1.27% | 0.98% | 1.18% | 1.12% | 1.37% | 1.24% | 0.99% | 1.18% | 0.99% |
Organon EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
EPS | - | - | - | - | - | - | - | - | $2.13 | - | - | $0.70 | $0.42 | $0.89 | $0.92 | $1.37 | $0.80 | $1.27 | $1.68 | $1.58 |
Avg Forecast | $1.01 | $0.96 | $1.03 | $1.03 | $0.93 | $0.90 | $1.08 | $0.98 | $0.81 | $1.05 | $0.97 | $1.17 | $0.92 | $1.10 | $1.17 | $1.30 | $1.24 | $1.44 | $1.42 | $1.73 |
High Forecast | $1.02 | $0.97 | $1.04 | $1.04 | $0.95 | $0.95 | $1.08 | $0.98 | $1.08 | $1.08 | $0.98 | $1.18 | $0.93 | $1.10 | $1.18 | $1.36 | $1.24 | $1.44 | $1.42 | $1.73 |
Low Forecast | $0.99 | $0.95 | $1.01 | $1.02 | $0.89 | $0.86 | $1.08 | $0.98 | $0.69 | $1.02 | $0.96 | $1.15 | $0.91 | $1.10 | $1.16 | $1.24 | $1.24 | $1.44 | $1.42 | $1.73 |
Surprise % | - | - | - | - | - | - | - | - | 2.63% | 0.00% | 0.00% | 0.60% | 0.46% | 0.81% | 0.78% | 1.05% | 0.64% | 0.88% | 1.19% | 0.91% |
Organon Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PFE | Pfizer | $27.76 | $44.76 | 61.24% | Hold |
BIIB | Biogen | $173.52 | $276.38 | 59.28% | Buy |
OGN | Organon | $16.92 | $24.00 | 41.84% | Buy |
MRK | Merck | $101.87 | $129.47 | 27.09% | Buy |
AZN | AstraZeneca | $71.43 | $84.33 | 18.06% | Buy |
BMY | Bristol-Myers Squibb Company | $55.45 | $64.57 | 16.45% | Hold |
JNJ | Johnson & Johnson | $158.24 | $179.13 | 13.20% | Buy |
SNY | Sanofi | $52.95 | $57.36 | 8.33% | Buy |
NVS | Novartis | $110.52 | $116.33 | 5.26% | Hold |
LLY | Eli Lilly and Company | $806.14 | $782.65 | -2.91% | Buy |
AMGN | Amgen | $316.91 | $293.15 | -7.50% | Buy |
GILD | Gilead Sciences | $89.84 | $81.32 | -9.48% | Buy |
ABBV | AbbVie | $200.47 | $174.04 | -13.18% | Buy |
OGN Forecast FAQ
Is Organon a good buy?
Yes, according to 3 Wall Street analysts, Organon (OGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of OGN's total ratings.
What is OGN's price target?
Organon (OGN) average price target is $24 with a range of $24 to $24, implying a 41.84% from its last price of $16.92. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Organon stock go up soon?
According to Wall Street analysts' prediction for OGN stock, the company can go up by 41.84% (from the last price of $16.92 to the average price target of $24), up by 41.84% based on the highest stock price target, and up by 41.84% based on the lowest stock price target.
Can Organon stock reach $30?
OGN's average twelve months analyst stock price target of $24 does not support the claim that Organon can reach $30 in the near future.
What are Organon's analysts' financial forecasts?
Organon's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.33B (high $6.35B, low $6.32B), average EBITDA is $2.33B (high $2.47B, low $2.19B), average net income is $1.16B (high $1.26B, low $1.06B), average SG&A $1.61B (high $1.7B, low $1.52B), and average EPS is $3.88 (high $3.96, low $3.8). OGN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.37B (high $6.42B, low $6.3B), average EBITDA is $2.19B (high $2.21B, low $2.17B), average net income is $1.05B (high $1.06B, low $1.03B), average SG&A $1.57B (high $1.59B, low $1.56B), and average EPS is $4.03 (high $4.07, low $3.97).
Did the OGN's actual financial results beat the analysts' financial forecasts?
Based on Organon's last annual report (Dec 2023), the company's revenue was $6.26B, beating the average analysts forecast of $6.24B by 0.43%. Apple's EBITDA was $1.55B, missing the average prediction of $2.16B by -28.11%. The company's net income was $1.02B, missing the average estimation of $1.06B by -3.29%. Apple's SG&A was $1.89B, beating the average forecast of $1.5B by 26.08%. Lastly, the company's EPS was $3.99, missing the average prediction of $4 by -0.24%. In terms of the last quarterly report (Dec 2023), Organon's revenue was $1.6B, beating the average analysts' forecast of $1.55B by 2.83%. The company's EBITDA was $370M, missing the average prediction of $534.05M by -30.72%. Organon's net income was $546M, beating the average estimation of $210.66M by 159.18%. The company's SG&A was $469M, beating the average forecast of $383.6M by 22.26%. Lastly, the company's EPS was $2.13, beating the average prediction of $0.811 by 162.64%